The effects of alpha-lipoic acid supplementation on fasting glucose and lipid profiles among patients with stroke: a systematic review and meta-analysis of randomized controlled trials

Tabrizi, Reza; Borhani‐Haghighi, Afshin; Mirhosseini, Naghmeh; Lankarani, Kamran Bagheri; Naghibzadeh‐Tahami, Ahmad; Akbari, Maryam; Heydari, Seyed Taghi; Sangari, Mojgan; Kolahdooz, Fariba; Raygan, Fariba; Asemi, Zatollah

doi:10.1007/s40200-019-00423-0

Cited by 9 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our result, one study concluded that, ALA improved peripheral insulin sensitivity in type 2 diabetes mellitus [9]. One meta-analysis showed a significant lower levels of serum glucose after ALA supplementation in patients with stroke [24]. The beneficial role of alpha lipoic acid in lowering the fasting plasma glucose may be connected to its effect in modulating adenosine monophosphate-activated protein kinase (AMPK) [25] in skeletal muscle and beta-cells [26]& [27], which subsequently potentiates the insulin-secretory response of β cells to glucose [28].…”

Section: Discussionsupporting

confidence: 90%

Alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy and different metabolic parameters

Elbadawy

Elmoniem

Elsayed

2021

Alexandria Journal of Medicine

View full text Add to dashboard Cite

Introduction: Alpha lipoic acid (ALA) is an antioxidant used in the treatment of neuroinflammation, diabetes and diabetic nephropathy. The current study aiming to gauge the effect of oral ALA on diabetic peripheral neuropathy, glycemic control, LDL-C, and HDL-C. Methods: This is a prospective, interventional study carried out on patients with type 2 diabetes mellitus (DM) who were following at the outpatient internal medicine & diabetes clinics at Benha University Hospital. Treatment with ALA for 3 months was given to patient with diabetic peripheral neuropathy. Data in the form of age, sex, body mass index (BMI), duration & treatment of DM, manifestations of peripheral neuropathy were collected. LDL-C, HDL-C, HbA1c, TSH, ALT, AST were measured before and after intervention. Peripheral neuropathy symptoms, nerve conduction velocities, cardiovascular (CV) tests of autonomic neuropathy, and cross-section area of the posterior tibial nerve were performed before and after treatment intervention. Results: 90 adult diabetic patients were recruited in the study, 42.2% were females and 57.8% were males with a median age of 50-60.3 years (IQR = 52). A statistically significant improvements of neuropathic symptoms, nerve conduction velocity, and cardiovascular autonomic neuropathy were noted after 3 months of administration of ALA (p ˂0.001). However, the cross-section area of the posterior tibial nerve at baseline and after treatment did not change significantly (p value of 0.84). There was a significant improvement in the BMI, HDL-C, LDL-C, HbA1c (p ˂ 0.001). Conclusion: Oral treatment with ALA might cause ameliorations of peripheral neuropathy, HbA1c, and LDL-C & HDL-C levels in diabetic patients. Our result failed to proof effect of ALA on nerve cross-section area. The global data encourage further studies with this medication as an ancillary treatment of DM2.Clinical trial registration: It was registered in clinical trial website; ClinicalTrials.gov Identifier (NCT number): NCT04322240.

show abstract

Section: Discussionsupporting

confidence: 90%

Alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy and different metabolic parameters

Elbadawy

Elmoniem

Elsayed

2021

Alexandria Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…In line with our findings, Rahimlou and colleagues also reported a significant decrease in HbA1c, CRP, and FPG after ALA supplementation in their study ( 52 ). Moreover, other studies found that ALA supplementation had beneficial effects on CRP levels ( 13 , 14 ) and FPG ( 53 ). We did not observe any effect of ALA supplementation on lipid profile, including TC, LDL cholesterol, and HDL cholesterol concentrations, which was in line with observations of previous studies ( 16 , 53 ).…”

Section: Discussionmentioning

confidence: 94%

“…Moreover, other studies found that ALA supplementation had beneficial effects on CRP levels ( 13 , 14 ) and FPG ( 53 ). We did not observe any effect of ALA supplementation on lipid profile, including TC, LDL cholesterol, and HDL cholesterol concentrations, which was in line with observations of previous studies ( 16 , 53 ). In contrast, serum TC and LDL cholesterol levels significantly decreased following ALA supplementation ( 11 , 54 ).…”

Section: Discussionmentioning

confidence: 94%

“…Our study has its advantages over the previous studies in terms of methodology. While in this study we included only patients with type 2 diabetes, the previous meta-analyses included patients with different health outcomes ( 13 , 53 , 54 ) and with smaller sample sizes ( 51 , 53 , 54 ). Furthermore, others included both oral and i.v.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

Jibril

Jayedi

Shab‐Bidar

2022

Endocrine Connections

View full text Add to dashboard Cite

Objective: To examine the dose-dependent influence of oral ALA supplementation on cardiometabolic risk factors in type 2 diabetes (T2D) patients. Design: We followed instructions outlined in the Cochrane Handbook for Systematic Reviews of Interventions and the Grading of Recommendations, Assessment, Development, and Evaluation Handbook to conduct our systematic review. The protocol of the study was registered in PROSPERO (CRD42021260587). Method: We searched PubMed, Scopus, and Web of Science to May 2021 for trials of oral ALA supplementation in adults with T2D. The primary outcomes were HbA1c, weight loss, and low-density lipoprotein cholesterol (LDL-C). Secondary outcomes included fasting plasma glucose (FPG), triglyceride, C-reactive protein, and blood pressure. We conducted a random-effects dose-response meta-analysis to calculate the mean difference (MD) and 95%CI for each 500 mg/d oral ALA supplementation. Non-linear dose-response meta-analyses were also conducted. Results: We included 16 trials with 1035 patients. Each 500 mg/d increase in oral ALA supplementation significantly reduced HbA1c, body weight, CRP, FPG, and TG. Dose-response meta-analyses indicated a linear decrement in body weight at ALA supplementation of more than 600 mg/d (mean difference 600 mg/d: -0.30 kg, 95%CI: -0.04, -0.57). A relatively J-shaped effect was seen for HbA1c (mean difference: -0.32%, 95%CI: -0.45, -0.18). Levels of FPG and LDL decreased up to 600 mg/d ALA intake. The point estimates of the certainty of evidence were below minimal clinically important difference thresholds for all outcomes. Conclusion: Despite significant improvements, the effects of oral ALA supplementation on cardiometabolic risk factors in T2D patients were not clinically important.

show abstract

“…These findings are particularly important because they encourage ALA use in a number of conditions in which ALA is actually proven to be effective. As a matter of fact, even though ALA supplementation has already been demonstrated to influence a broad spectrum of metabolic pathways including inflammation and glucose homeostasis [ 94 , 95 , 96 ], to the best of our knowledge this is the first time that ALA safety profile has been comprehensively evaluated through a pooled analysis of randomized placebo-controlled clinical studies.…”

Section: Discussionmentioning

confidence: 99%

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

et al. 2020

View full text Add to dashboard Cite

Alpha-lipoic acid (ALA) is a natural short-chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta-analysis of the available randomized placebo-controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA and 2294 assigned to placebo. A meta-analysis of extracted data suggested that supplementation with ALA was not associated with an increased risk of any treatment-emergent adverse event (all p > 0.05). ALA supplementation was safe, even in subsets of studies categorized according to smoking habit, cardiovascular disease, presence of diabetes, pregnancy status, neurological disorders, rheumatic affections, severe renal impairment, and status of children/adolescents at baseline.

show abstract

The effects of alpha-lipoic acid supplementation on fasting glucose and lipid profiles among patients with stroke: a systematic review and meta-analysis of randomized controlled trials

Cited by 9 publications

References 31 publications

Alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy and different metabolic parameters

Alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy and different metabolic parameters

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

Contact Info

Product

Resources

About